Technology | Nuclear Imaging | July 16, 2018

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software

New features bring high-level clinical capabilities to PET imaging in oncology and neurology

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software

July 16, 2018 — At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia, Siemens Healthineers announced U.S. Food and Drug Administration (FDA) clearance of syngo.via VB30 for Molecular Imaging (MI). The latest version of the company’s intelligent imaging software, syngo.via VB30 for MI has new features designed to bring advanced clinical capabilities to positron emission tomography/computed tomography (PET/CT) imaging in oncology and neurology.

syngo.via VB30 for MI automatically calculates a patient’s Deauville score – an internationally recognized scoring system used by oncologists in the initial staging and evaluation of therapeutic response for patients with Hodgkin lymphoma and most types of non-Hodgkin lymphoma. By avoiding the laborious, time-consuming task of manual Deauville score determination, clinicians can save time and increase efficiency.

Also, syngo.via VB30 for MI offers a unique platform for viewing and interpreting parametric PET images. Using dedicated layouts that permit simultaneous visualization of the summed Standard Uptake Values (SUV), the metabolic rate of glucose (MRFDG), and distribution volume images, readers can easily quantify the FDG uptake of these parametric indices.

Additionally, the new platform’s PET/CT and single photon emission computed tomography (SPECT)/CT hybrid VRT (volume-rendering technique) feature enables 3-D visualization of the disease state in a single image. This feature permits user-friendly interpretation of the cancer relative to anatomical landmarks.

Finally, syngo.via VB30 for MI offers improvements for the quantitative analysis of various neurological conditions via either self-created or widely used databases for various disease states. The assessment of striatal activity in the evaluation of Parkinson’s disease, hypometabolic seizure foci in the evaluation of epilepsy, and amyloid plaque burden in the evaluation of dementia can be conducted quantitatively. This ability provides more information to the reading physician to help increase diagnostic confidence.

For more information: www.usa.healthcare.siemens.com

Related Content

Figure 1

Figure 1

Feature | Information Technology | November 09, 2018 | By Jef Williams and Laurie Lafleur
Every year in late November tens of thousands of diagnostic imaging professionals from all over the globe descend upon...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages